Cynthia Baffi, MD
Pulmonary Disease · San Diego, CANPI 1417264227
Payments from drug & device makers
Across 39 payments — averaging $360.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- Olympus Corporation Of The Americas$2K
- Edwards Lifesciences$197
- Pulmonx Corporation$142
- Olympus America Inc.$133
- Merck$119
- plus $15 from 1 others
What the payments were for
- Travel & lodging$2,40017%
- Food & beverage$1,1688%
- Education$10,50075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 26 | $11,928 |
| Olympus Corporation Of The Americas | 8 | $1,535 |
| Edwards Lifesciences | 1 | $197 |
| Pulmonx Corporation | 1 | $142 |
| Olympus America Inc. | 1 | $133 |
| Merck | 1 | $119 |
| Cook Medical LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,068 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ambrisentan | 35 | $118,730 |
| AdempasRiociguat | 11 | $103,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $62,346 |
| Dupixent PenDupilumab | 13 | $42,763 |
| Spiriva RespimatTiotropium Bromide | 31 | $23,182 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $13,771 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $13,197 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,933 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $4,388 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $3,012 |
| Rifampin | 15 | $1,655 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $958 |
| Ethambutol Hcl | 11 | $934 |
| Azathioprine | 17 | $774 |
| Omeprazole | 43 | $660 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Diego
- Edward FedermanSan Diego$3.6M
- David PochSan Diego$1.5M
- Shari BrazinskySan Diego$522K
- Samir MakaniSan Diego$371K
- George ChengSan Diego$309K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.